Instrument and reagent vendors at ASHG 2026

Oct 20–24, 2026 Montréal, Canada ~7.5k attendees Website

49 instrument and reagent vendors are at ASHG 2026 — 84 presentations on the program and 34 with a booth in the exhibit hall. Most represented: Illumina (19 on the program), PacBio (6 on the program), Genomics (5 on the program). 34 of them have their own page in this guide. As of Sep 25, 2026.

All 1,062 organizations at ASHG 2026 →

Scientific focus
Top represented
Showing 1–5 of 49 organizations
OrganizationASHG 2026 Attendance
Illumina
San Diego, California
1 Senior Manager · 1 Vice President and Global Head of Advanced Science · 1 Sr Director, R&D · 1 Sr Director, Scientific Research-Advanced Platforms · 1 other presenter
Public company~8,600 people
Illumina sells DNA sequencing and array-based technologies. It serves research, clinical, and applied-market customers.
Illumina's Billion Cell Atlas alliance added AI-native drug developer Formation Bio and other members, widening its AI-biopharma customer reach.
›
Illumina's Billion Cell Atlas alliance added AI-native drug developer Formation Bio and other members, widening its AI-biopharma customer reach.
2026-07 · source
Illumina appointed Sullivan and Coletti to its executive leadership team, adding experienced decision-makers you may now be selling to.
2026-07 · source
Illumina launched StrataMap Spatial, a new whole-transcriptome spatial platform, giving customers an in-house option instead of buying elsewhere.
2026-06 · source
Source: company newsroom
Q2 2026 revenue $1.16B, up 9.5%
›
FY2026 guidance raised to $4.60-$4.64 billion, signaling steady growth and budget for sequencing purchases. · 2026-07-30
“Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025. For fiscal year 2026, we now expect total revenue of $4.60-$4.64 billion.”
Source: results release
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 701
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Session
Tue Oct 20
10:00 am
Strategies for Communicating Your Science
Plenary
Tue Oct 20
5:00 pm
Automated interpretation of rare disease genomes with deep graph attention
Collaborators: University of Oxford, Queen Mary University of London +1 more
Artificial intelligenceBioinformaticsVariant interpretationGenotype-phenotype correlations
Poster
Wed Oct 21
2:30 pm
Proximity-informed structural variant detection with Illumina TruPath Genome
Copy number/structural variationGenomic structureSequencing technology
Poster
Wed Oct 21
2:30 pm
A unified deep learning framework for quantitative splicing and transcript prediction
Collaborators: University of Oxford
Alternative splicingArtificial intelligenceDeep learningGenomics
Poster
Wed Oct 21
2:30 pm
Poster
Thu Oct 22
4:15 pm
Adapting Illumina Single Cell 3’ RNA Kit for 3′ Single Cell V(D)J Enrichment: Enabling Paired TCR α/β Recovery on the MiSeq™ i100 Plus
Alternative splicingSingle-cellImmune systemTranscriptome
Poster
Thu Oct 22
4:15 pm
Reliable detection of uniparental disomy from trio sequencing data using chromosome scale inheritance patterns
BioinformaticsClinical geneticsCopy number/structural variationChromosomal abnormalities
Poster
Fri Oct 23
2:30 pm
A streamlined method for simultaneous, high accurate methylation profiling and whole genome sequencing in FFPE sample types
MethylationGenomicsExome/genome sequencingEpigenetics
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Enabling flexible small-scale Illumina Spatial Technology workflow for benchtop sequencing platforms
Multi-omicsNon-coding RNARNASpatial transcriptomics
Poster
Fri Oct 23
2:30 pm
Resolving challenging genes for nonsyndromic sensorineural hearing loss using on flowcell proximity sequencing
Collaborators: Boston Children's Hospital
Sequencing technologyVariant callingCopy number/structural variationLaboratory genetics and genomics
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Advancing Whole-Exome Sequencing Through Optimized Coverage and Enrichment Performance
Exome/genome sequencingLaboratory genetics and genomicsGenetic testingGenomics
Poster
Fri Oct 23
2:30 pm
Targeted Profiling of CYP2D6, CYP2B6 and CYP21A2 in an Integrated Exome-Based NGS Workflow
Clinical testingComputational toolsCopy number/structural variationExome/genome sequencing
Poster
Fri Oct 23
2:30 pm
Poster
Fri Oct 23
2:30 pm
Inter-individual multiomics improves subtype resolution and risk stratification in cardiovascular disease
Collaborators: Henry Ford Health
Multi-omicsCardiovascular systemGene regulationMachine learning
PacBio
Menlo Park, California
1 Senior Product Manager, PacBio · 1 Bioinformatics Scientist · 1 Scientist · 1 Principal I Scientist, Bioinformatics · 1 other presenter
Public company
PacBio sells HiFi long-read sequencing systems, consumables, sample-prep kits, and analysis software to scientists and clinical researchers.
PacBio appointed Mark Van Oene as President and CEO effective August 5, 2026, a leadership change to watch during outreach.
›
PacBio appointed Mark Van Oene as President and CEO effective August 5, 2026, a leadership change to watch during outreach.
2026-08 · source
PacBio announced SPRQ-Nx chemistry and a software update for its Vega system, improving throughput and data output for HiFi sequencing.
2026-08 · source
SPRQ-Nx chemistry began shipping worldwide for PacBio's Revio platform, enabling sub-$300 HiFi genomes for large sequencing projects.
2026-05 · source
Source: company newsroom
Q2 2026 revenue $39.0M, down about 2%
›
Revenue dipped slightly year over year; FY2026 guidance is $155M-$165M, a modest growth outlook. · 2026-08-05
“"Revenue (in millions) | $39.0 | $39.8" / "PacBio expects revenue for the full year 2026 to be in the range of $155 million to $165 million."”
Source: results release
Booth
Exhibiting at Booth 605
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Poster
Wed Oct 21
2:30 pm
One-hour automated HMW DNA extraction from blood and saliva for HiFi sequencing
Laboratory genetics and genomicsLong-read sequencingMethodologySequencing technology
Poster
Wed Oct 21
2:30 pm
Long-read sequencing identifies and refines genome-wide methylation signals in multiple tumor types
Collaborators: Mayo Clinic, Memorial Sloan Kettering Cancer Center
BioinformaticsCancerEpigeneticsEpigenome-wide association studies
Poster
Thu Oct 22
4:15 pm
Kinnex-IsoSeq-WDL: Workflows for High Throughput Analysis of HiFi Kinnex Full-Length RNA Data
Collaborators: University of Virginia, Brandeis University +8 more
BioinformaticsRNALong-read sequencingTranscriptome
Poster
Thu Oct 22
4:15 pm
★ Reviewers’ Choice
Towards rapid HiFi long-read whole genome sequencing for time-critical rare disease applications
Long-read sequencingSequencing technologyExome/genome sequencingDiagnostics
Poster
Thu Oct 22
4:15 pm
Resolution of the D4Z4 repeat responsible for facioscapulohumeral muscular dystrophy with HiFi sequencing
Collaborators: Leiden University Medical Center
Long-read sequencingClinical geneticsCopy number/structural variationMuscular abnormalities
Genomics
Oxford, UK
1 Scientist · 1 Bioinformatician · 1 Chief Scientific Officer · 1 Research Scientist · 1 other presenter
Private company~150 people
Genomics sells AI-enabled human-genetics analytics and polygenic-risk testing to biopharma and healthcare providers.
Genomics launched Mystra AI, a human-genetics agentic AI platform for drug target discovery, already adopted by major biotechs.
›
Genomics launched Mystra AI, a human-genetics agentic AI platform for drug target discovery, already adopted by major biotechs.
2026-06 · source
Genomics partnered with Greywolf Therapeutics to research autoimmune disease targets using antigen modulation approaches.
2026-04 · source
Genomics rolled out its Health Insights predictive clinical tool nationwide across Great Britain, with new locations onboarding weekly.
2025-06 · source
Source: company newsroom
Raised $30M funding round (Mar 2021)
›
Backed significantly by Foresite Capital and F-Prime Capital; the most recent disclosed round. · 2021-03-01
“it has successfully completed a $30m funding round; Significant investment from leading life science investors Foresite Capital and F-Prime Capital.”
Source: funding announcement
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 1418
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Poster
Wed Oct 21
2:30 pm
★ Reviewers’ Choice
A machine learning framework for genome-wide signal-to-gene mapping achieves state-of-the-art causal gene prioritisation
Machine learningArtificial intelligenceGenomicsMulti-omics
Poster
Wed Oct 21
2:30 pm
A Genetics-First Framework for Predicting On-Target Safety Liabilities
GenomicsMachine learningPharmacogenomicsStatistical genetics
Poster
Thu Oct 22
4:15 pm
★ Reviewers’ Choice
Our Future Health: Emerging genetic insights from the world’s largest health research programme
DatabasesGenome-wide association studyPolygenic risk scorePopulation structure
Poster
Thu Oct 22
4:15 pm
Improved multi-trait colocalisation using MTColoc
Complex traitsComputational toolsExpression quantitative trait lociGenome-wide association study
Poster
Fri Oct 23
2:30 pm
★ Reviewers’ Choice
Evaluation of a novel AI agent for statistical genetics and target discovery
Artificial intelligenceStatistical genetics
2 Principal Applications Bioinformatician · 1 Senior Bioinformatician, Commercial Applications · 1 Senior Director of Commercial Applications · 1 Associate Director, Genomic Applications Bioinformatics
Public company~1,000 people
Oxford Nanopore sells real-time DNA/RNA sequencing devices, flow cells, and analysis software. Its customers include research, clinical, and biopharma teams.
Oxford Nanopore appointed David Miller as chief development and product officer and Conor McKechnie as chief marketing officer.
›
Oxford Nanopore appointed David Miller as chief development and product officer and Conor McKechnie as chief marketing officer.
2026-08 · source
Oxford Nanopore's MATRIX collaboration expanded to national CNS tumour classification across Norway, broadening its clinical sequencing reach.
2026-06 · source
Lonza and Oxford Nanopore launched a direct RNA sequencing solution for GMP mRNA quality control, opening an mRNA-manufacturing market.
2026-05 · source
Source: company newsroom
H1 2026 revenue £116.7M, up 10.5%
›
FY26 guidance is 16-20% constant-currency growth, excluding one-time $20M in licensing revenue. · 2026-08-19
““Group revenue was £116.7 million, which grew by 12.3% on a constant currency basis (CC), and 10.5% on a reported basis” / “FY26 revenue (no change): Constant-currency growth of 16–20%, excluding the $20 million non-recurring revenue””
Source: results release
Booth
Exhibiting at Booth 901
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Poster
Wed Oct 21
2:30 pm
★ Reviewers’ Choice
Large population-scale WGS with Oxford Nanopore Sequencing in UK Biobank
Collaborators: UK Biobank
Long-read sequencingCopy number/structural variationGenomicsMethylation
Poster
Wed Oct 21
2:30 pm
Profiling the Structure and Epigenetics of D4Z4 Arrays in FSHD Using Oxford Nanopore Sequencing
BioinformaticsLong-read sequencingMethylationMulti-omics
Poster
Wed Oct 21
2:30 pm
Hybridization-capture enrichment and full-length single-cell TCR profiling using Oxford Nanopore sequencing
Immune systemLong-read sequencingSingle-cellTargeted sequencing
Poster
Thu Oct 22
4:15 pm
Evaluation of Oxford Nanopore whole genome methylation sequencing for phenotype inference and association testing
EpigeneticsLong-read sequencingEpigenome-wide association studiesMethylation
Poster
Fri Oct 23
2:30 pm
★ Reviewers’ Choice
Beyond standard variant calling: analysis tools for resolving challenging medically relevant genes using nanopore whole-genome and digital panel data
BioinformaticsComputational toolsCopy number/structural variationTargeted sequencing
Attendee
Attendee
Attendee
Agilent Technologies
Santa Clara, California
2 R&D Scientist · 1 Product Marketing Director · 1 Product Manager
Public company~18,000 people
Agilent sells instruments, software, and consumables to laboratories. It also provides genomics assays, sample QC, and workflow services for research and diagnostics.
Agilent's board chair Koh Boon Hwee retired effective September 2026; Glenn Boehnlein joined the board, a leadership shift.
›
Agilent's board chair Koh Boon Hwee retired effective September 2026; Glenn Boehnlein joined the board, a leadership shift.
2026-09 · source
Agilent launched the S540MD digital pathology slide scanner in the US, adding a new pathology imaging product.
2026-09 · source
Agilent introduced the Cary 635 FTIR spectrometer, a new analytical instrument expanding its lab hardware lineup.
2026-09 · source
Source: company newsroom
Q3 FY2026 revenue $1.88B, up 8.1%
›
FY2026 revenue guidance is $7.49B-$7.51B, indicating steady growth across its instrument and consumables business. · 2026-08-26
“Revenue of $1.88 billion for the third quarter ended July 31, 2026, representing growth of 8.1% reported and up 7.3% core. Fiscal year 2026 revenue is now expected in the range of $7.49 billion to $7.51 billion.”
Source: results release
Currently hiring
›
Source: careers page
Booth
Exhibiting at Booth 1017
Wed, Oct 219:45am–4:30pmThu, Oct 229:45am–1:30pmFri, Oct 239:45am–4:30pm
Poster
Wed Oct 21
2:30 pm
Low-input gDNA integrity assessment for FFPE specimens using a multi-tissue sample set
Collaborators: Luxembourg Institute of Health
GenomicsLarge-scale biobanksLaboratory genetics and genomics
Poster
Wed Oct 21
2:30 pm
Poster
Wed Oct 21
2:30 pm

Explore the full ASHG 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Montréal. Leave your work email and we’ll be in touch.

Privacy

Download the full ASHG 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from instrument and reagent vendors

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Browse ASHG 2026 by

Exhibit hall

Not affiliated with or endorsed by the American Society of Human Genetics. Submit a correction